Correction: Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.
Xixi Ying, Zheng Shi, Rongjun Shao, Guangxian You, Zhengbo Song
Author Information
Xixi Ying: Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Zheng Shi: Postgraduate Training Base Alliance of Wenzhou Medical University, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
Rongjun Shao: Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Guangxian You: Department of Radiology and Oncology, Taizhou Cancer Hospital, Taizhou, China.
Zhengbo Song: Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Due to the delayed delivery of the request for a correction and the requirement from the Office of Zhejiang Chinese Medical University to standardize the institution's English translation, the editorial department of NEOPLASMA has issued a correction in response to the author's signed request: The affiliation of the first author has been changed from "Graduate School of Zhejiang University of Traditional Chinese Medicine" to "Graduate School, Zhejiang Chinese Medical University."
